Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

E Paubelle; P Coppo; L Garderet; L Azizi; D Bories; N-C Gorin; L Fouillard

首页> 外文期刊>Leukemia >Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

【24h】

Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

机译：硼替佐米治疗难治性多发性骨髓瘤终末期患者的浆细胞瘤可完全缓解，该患者在所有其他疗法（包括造血干细胞移植）均无效的情况下：可能会增强移植物抗肿瘤的作用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia》 |2005年第9期|共3页
作者
E Paubelle; P Coppo; L Garderet; L Azizi; D Bories; N-C Gorin; L Fouillard;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma. [J] . Poglod R, Kraj M, Kruk B, Leukemia and lymphoma . 2010,第12期

机译：免疫球蛋白E多发性骨髓瘤患者接受硼替佐米，阿霉素，地塞米松和自体干细胞移植治疗后完全缓解。
2. A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response. [J] . Robert M Rifkin, Andrew Greenspan, John F Schwerkoske, Investigational new drugs. . 2012,第2期

机译：硼替佐米的II期开放标签试验在患有多发性骨髓瘤的患者中进行，这些患者已经进行了自体外周血干细胞移植，但未能获得完全的应答。
3. Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma [J] . CavoM., PantaniL., PetrucciM.T., Blood: The Journal of the American Society of Hematology . 2012,第1期

机译：新诊断的多发性骨髓瘤患者自体造血干细胞移植后，硼替佐米-沙利度胺-地塞米松优于沙利度胺-地塞米松巩固治疗
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials [O] . Minjie Gao, Guang Yang, Ying Han, 2015

机译：多发性骨髓瘤自体造血干细胞移植后单剂硼替佐米或基于硼替佐米的方案作为巩固治疗：随机对照试验的荟萃分析
7. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect [O] . E Paubelle, P Coppo, L Garderet, 2005

机译：在终末期患者中使用耐火性多骨髓瘤的浆疟原虫在疟原虫细胞瘤中完全缓解，这些骨髓瘤失败了包括造血干细胞移植的所有其他疗法：可能的植物肿瘤效应的可能增强
8. Health Technology Review No. 12, August 1995. Hematopoietic Stem-CellTransplantation in Multiple Myeloma [R] . Handelsman, H. 1995

机译：卫生技术评论第12期，1995年8月。多发性骨髓瘤的造血干细胞移植

Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect

著录项

相似文献

相关主题

期刊订阅